首页> 外文期刊>European journal of gastroenterology and hepatology >Systemic inflammation and portal vein thrombosis in cirrhotic patients with gastroesophageal varices
【24h】

Systemic inflammation and portal vein thrombosis in cirrhotic patients with gastroesophageal varices

机译:胃肠静脉曲张肝硬化患者的全身炎症和门静脉血栓形成

获取原文
获取原文并翻译 | 示例
           

摘要

Background and aim Cirrhotic patients with gastroesophageal varices and non-tumoral portal vein thrombosis have a higher risk of re-bleeding and poor prognosis. This study aimed to analyze inflammatory biomarkers and thromboelastography in cirrhotic patients with portal vein thrombosis. Methods A total of 385 consecutive cirrhotic patients with gastroesophageal varices were prospectively enrolled between 1 December 2016, and 31 August 2017. Of these, 231 were eligible for analysis and were divided into portal vein thrombosis ( n = 103) and non-portal vein thrombosis ( n = 128) groups based on computerized tomography angiography findings. Results Patients with portal vein thrombosis generally had higher Child-Pugh scores than those without portal vein thrombosis (6.38 ± 0.12 vs. 5.81 ± 0.09, P < 0.001). The serum albumin levels were significantly lower in patients with portal vein thrombosis (35.90 ± 0.52 vs. 38.52 ± 0.43, P < 0.001). The portal vein thrombosis group had significant higher serum levels of interleukin 6 [4.85 (3.15–6.99) vs. 3.09 (2.06–5.20) pg/ml, P < 0.001] and tumor necrosis factor alpha [10.70 (7.60–15.20) vs. 9.07 (7.03–11.60) pg/ml, P = 0.020]. The interleukin 6 level was 2.5-fold higher in patients with portal vein thrombosis (adjusted odds ratio: 2.574; 95% confidential interval: 1.248–5.310). Thromboelastography showed that TEG-R, the reaction time, was significantly lower in the portal vein thrombosis group [5.20 (4.80–6.30) vs. 6.00 (5.20–6.95), P = 0.009], indicating enhanced coagulation activity. Conclusion This study confirmed the important role of systemic inflammation in portal vein thrombosis. Interleukin 6, an important inflammatory cytokine, is independently associated with portal vein thrombosis. The correlation between the interleukin 6 level and portal vein thrombosis requires further investigation.
机译:背景和AIM肝硬化患者胃食管静脉曲张和非肿瘤门静脉血栓形成具有更高的再出血和预后差的风险。本研究旨在分析肝硬化患者血管血栓形成的肝硬化患者炎性生物标志物和血栓球化。方法对胃食管域的总共385例连续385名肝硬化患者均在2016年12月1日期间招收,2017年8月31日。其中231例有资格分析,分为门静脉血栓形成(n = 103)和非门静脉血栓形成(n = 128)基于计算机断层造影血管造影结果的组。结果门静脉血栓形成的患者通常具有比没有门静脉血栓形成的更高的儿童-PUGH分数(6.38±0.12与5.81±0.09,p <0.001)。门静脉血栓形成患者血清白蛋白水平显着降低(35.90±0.52 vs.38.52±0.43,P <0.001)。门静脉血栓形成基团具有显着更高的白细胞介素6水平[4.85(3.15-6.99)与3.09(2.06-5.20)pg / ml,p <0.001]和肿瘤坏死因子α[10.70(7.60-15.20)与9.07(7.03-11.60)pg / ml,p = 0.020]。门静脉血栓形成的患者中白细胞介素6水平高2.5倍(调整的赔率比:2.574; 95%机密间隔:1.248-5.310)。血栓抑制术显示TEG-R,反应时间在门静脉血栓形成基团中显着降低[5.20(4.80-6.30),6.00(5.25-6.95),p = 0.009],表明增强的凝血活性。结论本研究证实了全身炎症在门静脉血栓形成中的重要作用。白细胞介素6是一个重要的炎症细胞因子,与门静脉血栓形成独立相关。白细胞介素6水平与门静脉血栓形成之间的相关性需要进一步调查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号